{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:16Z","timestamp":1791994576484,"version":"4.4.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1085","license":[{"start":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T00:00:00Z","timestamp":1451433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis is a chronic immunological skin disease and patients with this disorder typically experience a significant decrease in their quality of life. The disease is traditionally managed with topical and systemic agents (retinoids, ciclosporin A, methotrexate), but these treatment options are often long-term and their effects can be inconsistent and not ideal. The use of biological drugs in dermatological treatment is relatively new and began in the early 2000s. It should be noted that, in most countries, in order for biological treatment to be administered, specific criteria must be met. The current treatment options for psoriasis and psoriatic arthritis include tumour necrosis factor alpha (TNF-\u03b1) blockers, interleukin (IL)-12 and IL-23 inhibitors, T cell inhibitors and B cell inhibitors. These classes of biological drugs are characterised by protein structure as well as high molecular weight and their effectiveness is evaluated based on the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA) and the Dermatology Life Quality Index (DLQI). TNF-\u03b1 antagonists are one such class of biological drugs which includes infliximad, etanercept and adalimumab. Infliximab is a chimeric protein that is administered via intravenous infusions as a monotherapy in psoriasis vulgaris. Etanercept is indicated for use in both psoriasis vulgaris and psoriatic arthritis and it is the only drug that can be used as a treatment for children under the age of 8 with psoriasis. The drug is administered subcutaneously. Finally, adalimumab is a fully human monoclonal antibody that neutralises both free and membrane-bound TNF-\u03b1 and is used in the treatment of psoriasis vulgaris and psoriatic arthritis. This article reviews the latest research in the use of TNF-\u03b1 for the treatment of moderate to severe psoriasis and psoriatic arthritis. The results of research in this field are promising and confirm the effectiveness and safety of biological drugs as dermatological treatments for psoriasis. In particular, adalimumab, etanercept and infliximab are promising therapeutic options for patients with moderate to severe psoriasis and psoriatic arthritis who are unresponsive to conventional treatment strategies and they can significantly improve the quality of lives in patients with this disease.<\/jats:p>","DOI":"10.1136\/postgradmedj-2015-133419","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T03:18:37Z","timestamp":1451531917000},"page":"172-178","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["TNF-\u03b1 in a molecularly targeted therapy of psoriasis and psoriatic arthritis"],"prefix":"10.1093","volume":"92","author":[{"given":"Dominika","family":"Wcis\u0142o-Dziadecka","sequence":"first","affiliation":[{"name":"Department of Skin Structural Studies, Chair of Cosmetology, School of Pharmacy with Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Zbiciak-Nylec","sequence":"additional","affiliation":[{"name":"Chair and Department of Dermatology, School of Medicine in Katowice, Medical University of Silesia , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia","family":"Brzezi\u0144ska-Wcis\u0142o","sequence":"additional","affiliation":[{"name":"Chair and Department of Dermatology, School of Medicine in Katowice, Medical University of Silesia , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Mazurek","sequence":"additional","affiliation":[{"name":"Chair and Department of Molecular Biology, School of Pharmacy with Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,12,30]]},"reference":[{"key":"2023041308453596500_","first-page":"8","article-title":"The role of biological agents in dermatology","volume":"53","author":"Hury\u0144","year":"2007","journal-title":"Ann Acad Med Stetin"},{"key":"2023041308453596500_","first-page":"14","article-title":"Access to the biological treatment in Poland and around the world","volume":"6","author":"Jahnz-R\u00f3\u017cyk","year":"2010","journal-title":"Przew Lek"},{"key":"2023041308453596500_","first-page":"1","article-title":"Guidelines of Polish Dermatological Society on the treatment of psoriasis vulgaris and arthropathic psoriasis (psoriatic arthritis) with biological drugs","volume":"97","author":"Szepietowski","year":"2010","journal-title":"Przegl Dermatol"},{"key":"2023041308453596500_","first-page":"125","article-title":"Guidelines for high-quality use of biologic therapies in adults with plaque psoriasis","volume":"25","author":"Marques","year":"2012","journal-title":"Acta Med Port"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ad.2013.04.003","article-title":"Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","article-title":"The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics","volume":"52","author":"Coates","year":"2013","journal-title":"Rheumatology"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5114\/pg.2010.18472","article-title":"TNF superfamily: mechanisms of action, biologic functions and therapeutic possibilities","volume":"6","author":"Lubecka-Macura","year":"2010","journal-title":"Gastroenterol Rev"},{"key":"2023041308453596500_","first-page":"358","article-title":"Biology of tumor necrosis factor type alpha (TNF-alpha)","volume":"21","author":"Korobowicz","year":"2006","journal-title":"Pol Merkur Lekarski"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5114\/pg.2011.25377","article-title":"Blockers of tumour necrosis factor-\u03b1: mechanisms of action","volume":"5","author":"Eder","year":"2011","journal-title":"Gastroenterol Rev"},{"key":"2023041308453596500_","first-page":"1","volume-title":"Enbrel. Clinical application","author":"Kucharz","year":"2008"},{"key":"2023041308453596500_","first-page":"11","article-title":"The role of tumor necrosis factor (TNF-\u03b1) metabolism","volume":"58","author":"Olszanecka-Glinianowicz","year":"2005","journal-title":"Wiad Lek"},{"key":"2023041308453596500_","volume-title":"The pleiotropic effects of TNF-alpha in non-Hodgkin lymphomas [Doctoral dissertation]","author":"Gola","year":"2007"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Therapeut"},{"issue":"Suppl 1","key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF03325638","article-title":"Infliximab in psoriasis and psoriatic arthritis","volume":"27","author":"Papoutsaki","year":"2013","journal-title":"BioDrugs"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12026-013-8410-2","article-title":"Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab","volume":"56","author":"Lora","year":"2013","journal-title":"Immunol Res"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50\u2005mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1586\/1744666X.2013.836060","article-title":"Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response","volume":"9","author":"Hsu","year":"2013","journal-title":"Expert Rev Clin Immunol"},{"key":"2023041308453596500_","first-page":"468","article-title":"The biological drugs therapy for psoriasis: own experience","volume":"6","author":"Tyc-Zdrojewska","year":"2009","journal-title":"Forum Med Rodz"},{"key":"2023041308453596500_","first-page":"189","article-title":"Etanercept significantly improves quality of life of patients with psoriasis: current literature review","volume":"9","author":"Reich","year":"2007","journal-title":"Dermatol Klin"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2013.03.031","article-title":"A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis","volume":"69","author":"Lebwohl","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1684\/ejd.2013.2173","article-title":"Clinical and economic impact of etanercept in real-life: a prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER)","volume":"23","author":"Larsen","year":"2013","journal-title":"Eur J Dermatol"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/09546634.2013.848260","article-title":"Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment","volume":"25","author":"Puig","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"2023041308453596500_"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s13555-013-0030-1","article-title":"Long-term cost-effectiveness analysis of etanercept and adalimumab for plaque psoriasis not associated with arthritis","volume":"3","author":"Ruano","year":"2013","journal-title":"Dermatol Ther"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/09546634.2012.755255","article-title":"Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting","volume":"24","author":"Bonafede","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/09546634.2012.751483","article-title":"Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice","volume":"24","author":"Van den Reek","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.12543","article-title":"Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre","volume":"169","author":"L\u00f3pez-Ferrer","year":"2013","journal-title":"Br J Dermatol"},{"key":"2023041308453596500_","first-page":"92","article-title":"Biologic therapy in chosen skin diseases","volume":"7","author":"Jenerowicz","year":"2006","journal-title":"Przew Lek"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.4.4.637","article-title":"Adalimumab: a review of side effects","volume":"4","author":"Scheinfeld","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"2023041308453596500_","first-page":"1089","article-title":"Possible drug-drug interaction between adalimumab and duloxetine and\/or pregabalin in a psoriasis patient","volume":"12","author":"Gupta","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamadermatol.2013.8347","article-title":"Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up","volume":"150","author":"Menting","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjd.12341","article-title":"Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study","volume":"169","author":"Mahil","year":"2013","journal-title":"Br J Dermatol"},{"key":"2023041308453596500_","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"Br J Dermatol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/92\/1085\/172\/49842147\/postgradmedj-92-172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/92\/1085\/172\/49842147\/postgradmedj-92-172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T09:58:12Z","timestamp":1692179892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/92\/1085\/172\/6984324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,30]]},"references-count":36,"journal-issue":{"issue":"1085","published-online":{"date-parts":[[2015,12,30]]},"published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2015-133419","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,3]]},"published":{"date-parts":[[2015,12,30]]}}}